Multidisciplinary Tumor Board: A Single Institution’s Perspective

Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic

COVID-19 and Thoracic Malignancies

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies

The RAMES Study: A New Strategy of Targeting Angiogenesis in Mesothelioma

Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role

Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status

First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC

Deeper Dive: A Plethora of Prediction Models

Lung Cancer Diagnosis and Staging During COVID-19

Can We Use the Word ‘Cure’ for a Subset of Selected Patients With Advanced NSCLC?

Small Steps Forward in SCLC: Is a Giant Leap on the Horizon?